Clazakizumab

Clazakizumab (CSL300) is CSL Behring's anti-IL-6 monoclonal antibody being tested in POSIBIL6ESKD (NCT05485961), a Phase 2b/3 adaptive trial targeting reduction of major adverse cardiovascular events (MACE) in adults with end-stage kidney disease on maintenance dialysis [1]. The bet: chronic inflammation, marked by persistently elevated C-reactive protein, drives residual cardiovascular risk in dialysis patients even after standard-of-care blood pressure control and renin-angiotensin blockade. Lipid lowering, notably, does not fix the dialysis-CV problem. The 4D trial (atorvastatin in diabetic hemodialysis patients) and AURORA (rosuvastatin in general hemodialysis patients) both cut LDL by roughly 40% and both failed to reduce the primary composite cardiovascular endpoint [10][11]. That negative statin evidence is what makes the inflammation-not-lipid hypothesis particularly compelling in ESKD. This is the same residual inflammatory risk thesis validated by CANTOS with canakinumab (anti-IL-1β), applied one step downstream in the cytokine cascade and in a much sicker population [6]. Phase 2b data published in Nat Med 2024 showed 86-97% hs-CRP suppression across doses at week 12, at the pharmacodynamic ceiling for any anti-inflammatory agent [2]. External validation arrived on Feb 18, 2026: Eli Lilly paid CSL $100M upfront (plus undisclosed milestones and royalties) for exclusive rights to clazakizumab in all indications except ESKD cardiovascular prevention, which CSL retained exclusively [12]. A top-5 pharma independently priced the antibody, and CSL kept the indication it believes is most valuable. What's at stake: a new therapeutic class for ESKD cardiovascular disease, a population where essentially nothing has moved MACE in decades. Novo Nordisk's ziltivekimab is running an adjacent (not identical) anti-IL-6 program in non-dialysis CKD patients with established ASCVD [7][13].

Clazakizumab is a repurposed asset with mixed prior clinical history moving into a much larger indication. It was originally developed by Vitaeris (Vancouver) for antibody-mediated rejection in kidney transplant recipients, with early Phase 1/2 data in a small cohort (NCT03380377) [3]. The IMAGINE Phase 3 trial in chronic active antibody-mediated rejection was terminated early at interim analysis after failing to meet the primary endpoint of time to all-cause allograft loss or irreversible loss of allograft function [14]. This Phase 3 failure is on record and matters for the asset's overall clinical narrative, though the mechanistic rationale for the AMR indication (blocking IL-6 driven donor-specific antibody production and graft inflammation) differs from the ESKD-CV thesis (blocking systemic inflammation to prevent MACE), so the read-across to POSIBIL6ESKD is indirect rather than direct. CSL acquired Vitaeris in 2020 and pivoted the antibody toward the ESKD cardiovascular outcomes opportunity. The Phase 2b portion of POSIBIL6ESKD is currently recruiting, with a combined 2b/3 enrollment target of 3,110 patients [1]. Phase 2b is dose selection with hs-CRP as the primary endpoint; Phase 3 is event-driven MACE. A parallel Phase 1b PK study in Chinese ESKD subjects (NCT07619820) is separately enrolling, suggesting CSL is building a global regulatory package [4]. No FDA breakthrough therapy, fast track, or orphan designation has been publicly disclosed for the cardiovascular indication. The adaptive 2b/3 design lets CSL transition into outcomes evaluation without a full protocol restart, saving 2-3 years versus sequential development. On Feb 18, 2026, CSL and Eli Lilly announced an exclusive licensing agreement in which Lilly paid CSL $100M upfront, plus undisclosed clinical, regulatory, and commercial milestones and tiered royalties on global net sales, for rights to clazakizumab in all indications except ESKD cardiovascular prevention, which CSL retains exclusively [12]. This is the most important external validation event for the asset. A top-5 pharma independently priced the antibody in the mid-nine-figures upfront, and CSL held back the indication most central to its own long-range strategy, a strong tell about CSL's internal read of the ESKD-CV opportunity. Realistic timeline: Phase 2b dose selection announcement in 2026 or 2027, Phase 3 event accrual through 2027-2029, BLA submission no earlier than 2029-2030. CSL Limited (the parent company; CSL Behring is its pharmaceutical segment) reported approximately $14.8B USD in FY2024 total group revenue and has cardiovascular commercial infrastructure through its plasma therapeutics franchise [8].

IL-6, or interleukin-6, is a signaling protein that immune cells release when something goes wrong. It is the alarm bell for inflammation. When IL-6 hits liver cells, they respond by pumping out C-reactive protein (CRP), the biomarker clinicians use to measure whether inflammation is smoldering in the background. In healthy people, IL-6 spikes during an infection and returns to baseline. In dialysis patients, that alarm never turns off. The artificial dialysis membrane triggers complement activation, uremic toxins are pro-inflammatory, and comorbidities (diabetes, heart failure, calcified vessels) keep IL-6 chronically elevated. Persistent IL-6 accelerates atherosclerosis and correlates strongly with cardiovascular death. Critically for framing the unmet need, statins do not solve the dialysis-CV problem. The 4D trial (atorvastatin in diabetic hemodialysis patients, Wanner NEJM 2005) and AURORA (rosuvastatin in general hemodialysis patients, Fellström NEJM 2009) both cut LDL cholesterol by roughly 40% but produced no significant reduction in the primary composite cardiovascular endpoint [10][11]. That lipid-neutral outcome in dialysis is exactly what motivates the inflammation-not-lipid hypothesis for this population. The residual inflammatory risk hypothesis got its clearest validation in CANTOS (2017), where canakinumab, an antibody against IL-1β (a cytokine upstream of IL-6), cut MACE by 15% in stable coronary patients [6]. That trial proved anti-inflammatory therapy can move CV outcomes independent of lipid lowering. IL-6 sits downstream of IL-1β and is thought to be the more direct vascular driver, so blocking IL-6 should, in principle, give a cleaner and larger effect. Clazakizumab is a humanized IgG1 antibody that binds circulating IL-6 and prevents it from engaging its receptor. Humanized means most of the antibody's amino-acid sequence matches native human immunoglobulin, with only the antigen-binding region derived from the original mouse antibody; this reduces immunogenicity so the drug can be dosed chronically without the patient's own immune system attacking it. Chertow et al. (Nat Med 2024) showed 86-97% suppression of hs-CRP at week 12 in maintenance dialysis patients across the tested doses [2]. Population PK/PD modeling supports monthly subcutaneous dosing [5]. The pharmacology is not the question. The clinical translation is.

POSIBIL6ESKD (NCT05485961) is a two-part adaptive Phase 2b/3 trial [1]. Part 1 (Phase 2b) enrolls adults on maintenance hemodialysis with elevated hs-CRP, randomizing across multiple clazakizumab doses versus placebo. Primary endpoint is change from baseline in log-transformed hs-CRP, a pharmacodynamic readout rather than a clinical outcome. Part 2 (Phase 3) uses the selected dose and evaluates MACE, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Combined planned enrollment: 3,110 patients. Sponsor: CSL Behring. Status: RECRUITING per ClinicalTrials.gov. The design choices are defensible. hs-CRP enrichment recruits patients with real inflammatory burden, avoiding dilution by low-CRP non-responders. Placebo control preserves interpretability. The seamless adaptive structure lets CSL move into outcomes without pausing to write a new protocol. MACE is a hard endpoint regulators respect. Population PK modeling has already been published, so dose selection has a quantitative anchor [5]. The risks are population-specific. Dialysis patients have high all-cause mortality, and competing risks (infection, sudden cardiac death from electrolyte shifts, dialysis access complications) can dilute a MACE signal. If infection deaths rise on the active arm (a known on-target IL-6 blockade risk), a positive MACE signal could be offset by neutral or worse all-cause mortality. Enrollment pace since the 2022 study start is not publicly disclosed, and 3,110 dialysis patients is a heavy operational lift.

Our model estimates a 12% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 27%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and more secondary endpoints than usual; it is held back by heavier-than-usual blinding and the sponsor's thin or weak approval record. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: the mechanism-to-biomarker link is airtight (hs-CRP drops), but biomarker-to-MACE translation in dialysis has never been demonstrated. CANTOS enrolled stable coronary artery disease patients, not ESKD [6]. Dialysis CV pathology is dominated by vascular calcification, arrhythmias from potassium and calcium shifts, and left ventricular hypertrophy, not classic atherosclerotic plaque rupture. The biology of inflammation may matter less in this population than in the CANTOS cohort. The failure of statins in 4D and AURORA is instructive: dialysis-CV pathology has repeatedly refused to respond to interventions that work in the general CV population [10][11]. The IMAGINE Phase 3 failure in AMR also shows clazakizumab can miss on a hard clinical endpoint even after positive Phase 2 signal [14]. Network meta-analyses of IL-6 blockade in transplant rejection show variable effect sizes, a cautionary signal for a first-in-CV-outcomes readout [9]. Safety risk: IL-6 blockade elevates infection risk. This is on-target, dose-dependent, and documented for tocilizumab and sarilumab (anti-IL-6R antibodies in rheumatoid arthritis). Dialysis patients already have high baseline infection mortality from catheter-related bacteremia and peritonitis. A dose that suppresses hs-CRP by 97% may also blunt the febrile and CRP response to sepsis, delaying diagnosis. Neutropenia, hepatotoxicity, and GI perforation are class effects requiring monitoring. Execution risk: 3,110 patients across dialysis clinics is operationally heavy [1]. Clinic networks are consolidated (DaVita, Fresenius), which helps site access but concentrates recruitment risk. The study has been RECRUITING since 2022 with no public enrollment update. Commercial risk: dialysis reimbursement in the US operates under CMS ESRD bundled payment, which limits ancillary drug cost absorption. Biologics historically sit outside the bundle (billed separately under Part B) but face payer scrutiny and periodic threats of bundle inclusion. An expensive antibody layered on top of already-expensive dialysis will need a clear NNT and mortality benefit for formulary access. Novo Nordisk's ziltivekimab is running in a different (non-dialysis CKD) population but a positive ZEUS readout would shape payer expectations and reimbursement anchoring for the class [7][13].

Worth watching, moderately-plus. Two updates materially change the picture since prior versions of this writeup. First, Eli Lilly's Feb 2026 in-licensing deal, $100M upfront plus undisclosed milestones and royalties for rights outside ESKD-CV, is a hard external price signal on the antibody. The fact that CSL retained ESKD-CV exclusively signals that this is CSL's crown-jewel indication, not something they were willing to co-develop away [12]. Second, the IMAGINE Phase 3 failure in chronic active AMR is on the clinical record and cannot be papered over, though the mechanism-to-endpoint rationale in AMR (graft inflammation, DSA control) differs enough from the CV thesis (systemic inflammation to MACE) that it is not a straight negative read-across [14]. Net: this remains the second serious swing at anti-cytokine therapy for cardiovascular outcomes, with a validated upstream proof point in CANTOS [6]. CSL Limited is a serious sponsor, roughly $14.8B USD in group revenue in FY2024, with cardiovascular commercial infrastructure through its plasma therapeutics franchise [8]. Not a small biotech throwing a Hail Mary. The signal to watch: Phase 2b dose selection results, expected 2026-2027. The specific question is whether CSL picks a dose that suppresses hs-CRP below 2 mg/L (the CANTOS responder threshold) without an excess infection signal. If they do, the Phase 3 MACE readout in 2028-2029 becomes a real event that could open a new therapeutic class for ESKD-CV, where lipid lowering has already failed and no anti-inflammatory therapy exists [10][11]. The competitive question is more thesis-level than direct market share. Novo Nordisk's ZEUS trial (6,376 patients) evaluates ziltivekimab in non-dialysis CKD (eGFR roughly 15 to under 60 mL/min/1.73m²) with established ASCVD and hs-CRP ≥2 mg/L, explicitly a different population from POSIBIL6ESKD's dialysis-dependent patients [7][13]. A ziltivekimab win validates the inflammation-CV thesis and de-risks POSIBIL6ESKD without stealing its market. A ziltivekimab failure on safety could poison the entire IL-6 well. The two programs are not head-to-head competitors for the same patients; they are a two-arm bet on the same underlying biology. Check back: Q4 2026 for Phase 2b dose selection or AHA/ACC presentations; 2027 for enrollment status; 2028-2029 for Phase 3 MACE readout, which is the terminal event.